Skip to main content
logo
Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
2.880
-0.100 (-3.36%)
At close: Aug 10, 2026, 4:00 PM EDT
2.910
+0.030 (1.04%)
After-hours: Aug 10, 2026, 7:57 PM EDT

Virax Biolabs Group Financials Overview

Millions USD. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
0.010.010.010.160.01-
Revenue Growth
316.04%96.23%-95.95%1727.11%--
Gross Profit
0.010.01-0.050.05-0-
Operating Income
-6.4-6.4-6.08-6.53-5.73-1.73
Net Income
-5.02-5.02-6.06-6.73-5.46-1.71
Earnings Per Share
-12.64-12.64-40.62-83.90-128.25-44.75
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
6.446.444.233.599.350.02
Total Debt
0.410.410.380.220.150
Net Cash (Debt)
6.026.023.853.369.210.02
Net Cash Growth
114.59%56.40%14.47%-63.45%42216.09%23.47%
Net Cash Per Share
15.1515.1525.8141.93216.520.57

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
-4.62-4.62-4.56-6.4-4.18-0.81
Capital Expenditures
-0.26-0.26-0.6-0.95--
Free Cash Flow
-4.88-4.88-5.17-7.35-4.18-0.81
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
61.90%61.90%-838.21%32.34%-15.94%-
Operating Margin
-51515.20%-51515.20%-95984.90%-4171.92%-66963.70%-
Pretax Margin
-47753.55%-47753.55%-97992.31%-4308.38%-63751.47%-
Profit Margin
-40507.00%-40507.00%-95833.70%-4308.38%-63751.50%-
FCF Margin
-39263.60%-39263.60%-81621.60%-4698.55%-48823.40%-

Valuation
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PS Ratio
184.76256.32781.8411.801262.86-